In Maiden Meet, Indian And Chinese Drug Regulators Discuss More Access For Indian Exporters To Pharma Market In China

In the first ever meeting of Indian and Chinese drug regulators, Indian representatives pressed their counterparts for a clear roadmap to open up the Chinese pharmaceuticals market for Indian exports, reports The Economic Times.

The crucial meeting took place on Friday (21 June) at Shanghai. The meeting gains significance as Indian officials have for long been pressing over China to allow Indian companies wider access to the Chinese pharmaceuticals market which is presently under pressure because of high prices of cancer and generic drugs.

The meeting went on for as much as nine hours and included senior officials from the Ministry of Commerce and also diplomats to aid the discussion. The Indian Ambassador to China, Vikram Misri, also emphasised the need to hold such meetings in a regular fashion.

The meeting deliberated upon different subjects in six sessions, such as regulatory overview of the National Medical Products Administration (NMPA), registration of imported drugs in China, Indian regulatory system, drug procurement system in China, NMPA overseas inspections and compliance guide, API (Active Pharmaceutical Ingredient) registration process in China.